Oxidative Stress in the Progression of Alzheimer Disease in the Frontal Cortex
Overview
Authors
Affiliations
We investigated oxidative stress in human postmortem frontal cortexfrom individuals characterized as mild cognitive impairment (n= 8), mild/moderate Alzheimer disease (n = 4), and late-stage Alzheimer disease (n = 9). Samples from subjects with no cognitive impairment (n = 10) that were age- and postmortem interval-matched with these cases were used as controls. The short postmortem intervalbrain samples were processed for postmitochondrial supernatant, nonsynaptic mitochondria, and synaptosome fractions. Samples were analyzed for several antioxidants (glutathione, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, glucose-6-phosphate dehydrogenase, superoxide dismutase, catalase) and the oxidative marker, thiobarbituric acid reactive substances. The tissue was also analyzed for possible changes in protein damage using neurochemical markers for protein carbonyls, 3-nitrotyrosine, 4-hydroxynonenal, andacrolein. All 3 neuropil fractions (postmitochondrial supernatant, mitochondrial, and synaptosomal) demonstrated significant disease-dependent increases in oxidative markers. The highest changes were observed in the synaptosomal fraction. Both mitochondrial and synaptosomal fractions had significant declines in antioxidants (glutathione, glutathione peroxidase, glutathione-S-transferase, and superoxide dismutase). Levels of oxidative markers significantly correlated with Mini-Mental Status Examination scores. Oxidative stress was more localized to the synapses, with levels increasing in a disease-dependent fashion. These correlations implicate an involvement of oxidative stress in Alzheimer disease-related synaptic loss.
Elyasi L, Rosenholm J, Jahanshahi M, Jesmi F Mol Neurobiol. 2025; .
PMID: 39946000 DOI: 10.1007/s12035-025-04740-9.
Wan Ngah W, Ahmad H, Ankasha S, Makpol S, Tooyama I Antioxidants (Basel). 2025; 13(12.
PMID: 39765832 PMC: 11673287. DOI: 10.3390/antiox13121504.
Alves F, Lane D, Nguyen T, Bush A, Ayton S Signal Transduct Target Ther. 2025; 10(1):2.
PMID: 39746918 PMC: 11696223. DOI: 10.1038/s41392-024-02088-5.
Therapeutic agents for Alzheimer's disease: a critical appraisal.
Weinstock M Front Aging Neurosci. 2024; 16:1484615.
PMID: 39717349 PMC: 11663918. DOI: 10.3389/fnagi.2024.1484615.
Oxidative stress and chronic cerebral hypoperfusion: An overview from preclinical rodent models.
Kimura S, Iwata M, Takase H, Lo E, Arai K J Cereb Blood Flow Metab. 2024; 45(3):381-395.
PMID: 39663901 PMC: 11635795. DOI: 10.1177/0271678X241305899.